Altimmune, Inc. (ALT)

NASDAQ • Healthcare

$2.12

-$0.04 (-2.3%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$2.16

Previous Close$2.12

Day Range$2.06 - $2.2

Avg. Volume (3M)3.7M

Market Cap$412.3M

52 Week Range

$2.06$6.44

Next EarningsIn 11 daysNov 5, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)

$31K

Net Income (TTM)

-$91.7M

EPS (TTM)

-$0.78

ROA (TTM)

-17.4%

Current Ratio

26.78

Dividend Yield

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+15.6%Q3 2025-$0.27

+27.6%Q4 2025-$0.21

-8.0%Q1 2026-$0.27

+28.0%Q2 2026-$0.18

+11.4%Q3 2026-$0.12

Nov 5

in 11 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Beat +11.4%

Altimmune’s second fiscal quarter of 2026 earnings topped consensus expectations, with EPS of -$0.12 topping the -$0.14 estimate by $0.02 in results reported August 11, 2026, based on preliminary figures. The clinical-stage biotechnology company, which is centered on programs including pemvidutide and HepTcell, posted a GAAP net loss of about $22.8 million, representing a -3.1% year-over-year change from a net loss of roughly $22.1 million a year ago, while GAAP operating loss came in at about $26.2 million. Cash usage remained elevated, with negative operating cash flow of about $24.2 million for the quarter. For the next period, consensus calls for EPS of -$0.14 on revenue of $1,750.00.

Next report — what to expect

Altimmune, Inc. (ALT) reports earnings on November 5, 2026. Wall Street is looking for consensus EPS of -$0.14 on revenue of $1,750.00. For trailing context, revenue was -100.0% year over year last quarter. Altimmune has beaten EPS in 7 of its 8 most recent quarters.

View full earnings history

About Altimmune, Inc.

Altimmune, Inc. develops immune-focused drug candidates as a clinical-stage Biotechnology company listed on the NASDAQ as ALT. The company centers on two programs, pemvidutide and HepTcell, operates from Gaithersburg, Maryland, and traces its history to a 1997 founding as Vaxin Inc.

Name

Altimmune, Inc.

CEO

Jerome Benedict Durso

Website

altimmune.com

Industry

Healthcare

Year Founded

1997

Employees

Today's Snapshot

AI-generated

ALT closed 2.3% below yesterday's close, in line with a weaker sector. ALT closed within 2.9% of its 52-week low of 2.06.

Trading Volume

Below 10d avg (3.4M)

2.5M

vs S&P 500 Today

Underperforming Market

-1.78%

Updated: October 23, 2026 at 20:20 UTC

Technical Indicators

2 Buy0 Neutral6 Sell

ALT is a Strong Sell with a pronounced downward tendency; ADX above 38 signals a strong directional move lower while the stock trades well below its short-, medium- and 200‑day averages. Oscillators show deeply oversold readings (notably RSI and stochastic), yet momentum and MACD remain negative, so oversold signals coexist with continued selling pressure. On‑balance volume is heavily negative, reinforcing distribution, and ATR shows elevated percentage volatility. The classic pivot sits above current levels, representing additional resistance. Technical takeaway: Overall bias is Strong Sell.

All signals

EMA (5 indicators)$2.30 - $3.38
Sell
RSI (14)23.21
Buy
Stochastic %K (14, 3, 3)7.18
Buy
MACD Level (12, 26)-0.23
Sell

Peers & Related Assets

VIRVir Biotechnology, Inc.

$10.57+1.3%

ABUSArbutus Biopharma Corp

$4.2-0.2%

ENTAEnanta Pharmaceuticals, Inc.

$11.64+0.2%

GPCRStructure Therapeutics Inc.

ASMBAssembly Biosciences, Inc.

INDPIndaptus Therapeutics, Inc.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.